CN106879253A - 新生儿微生物组补充 - Google Patents

新生儿微生物组补充 Download PDF

Info

Publication number
CN106879253A
CN106879253A CN201580025721.0A CN201580025721A CN106879253A CN 106879253 A CN106879253 A CN 106879253A CN 201580025721 A CN201580025721 A CN 201580025721A CN 106879253 A CN106879253 A CN 106879253A
Authority
CN
China
Prior art keywords
organisms
fetus
probiotic micro
probiotic
oral cavity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580025721.0A
Other languages
English (en)
Chinese (zh)
Inventor
B.梅尔斯塔姆
K.亚加尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaya
Original Assignee
Biogaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaya filed Critical Biogaya
Publication of CN106879253A publication Critical patent/CN106879253A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201580025721.0A 2014-05-20 2015-05-20 新生儿微生物组补充 Pending CN106879253A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000842P 2014-05-20 2014-05-20
US62/000842 2014-05-20
PCT/EP2015/061181 WO2015177246A2 (en) 2014-05-20 2015-05-20 Neonatal microbiome supplementation

Publications (1)

Publication Number Publication Date
CN106879253A true CN106879253A (zh) 2017-06-20

Family

ID=53284210

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580025721.0A Pending CN106879253A (zh) 2014-05-20 2015-05-20 新生儿微生物组补充

Country Status (9)

Country Link
US (1) US20170216375A1 (cg-RX-API-DMAC7.html)
EP (1) EP3145520A2 (cg-RX-API-DMAC7.html)
JP (1) JP2017515881A (cg-RX-API-DMAC7.html)
KR (1) KR20170005806A (cg-RX-API-DMAC7.html)
CN (1) CN106879253A (cg-RX-API-DMAC7.html)
AU (1) AU2015261869A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002732A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016015153A (cg-RX-API-DMAC7.html)
WO (1) WO2015177246A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739814A (zh) * 2018-07-24 2021-04-30 生命大地女神有限公司 使用能够增加腺苷水平的细菌菌株的治疗方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
AU2015340605B2 (en) 2014-10-29 2021-06-24 Biogaia Ab Use of L. reuteri for recovery of microbiota dysbiosis in early life
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
ES2928223T3 (es) * 2018-07-24 2022-11-16 Biogaia Ab Selección y uso de bacterias de apoyo a la melatonina para reducir los cólicos infantiles
WO2020028871A1 (en) * 2018-08-03 2020-02-06 Research Institute At Nationwide Children's Hospital Prenatal probiotic formulations
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
JP7662538B2 (ja) 2019-06-03 2025-04-15 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 敗血症および壊死性腸炎誘発神経発達不全の予防のためのプレバイオティクス製剤
EP4436407A1 (en) 2021-11-22 2024-10-02 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
US20250255909A1 (en) * 2022-04-14 2025-08-14 Washington University Prevotella copri formulations and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268006A1 (en) * 2004-10-05 2008-10-30 Probi Ab Probiotic Lactobacillus Strains for Improved Vaginal Health
CN102159226A (zh) * 2008-07-21 2011-08-17 雀巢产品技术援助有限公司 增加剖宫产出生婴儿的IgA分泌的益生菌
CN102575224A (zh) * 2009-09-11 2012-07-11 美赞臣营养品公司 用于预防和治疗过敏的益生菌衍生的无活力材料
US20130121932A1 (en) * 2003-01-29 2013-05-16 Bo Mollstam Selection and Use of Lactic Acid Bacteria for Reducing Dental Caries and Bacteria Causing Dental Caries
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121932A1 (en) * 2003-01-29 2013-05-16 Bo Mollstam Selection and Use of Lactic Acid Bacteria for Reducing Dental Caries and Bacteria Causing Dental Caries
US20080268006A1 (en) * 2004-10-05 2008-10-30 Probi Ab Probiotic Lactobacillus Strains for Improved Vaginal Health
CN102159226A (zh) * 2008-07-21 2011-08-17 雀巢产品技术援助有限公司 增加剖宫产出生婴儿的IgA分泌的益生菌
CN102575224A (zh) * 2009-09-11 2012-07-11 美赞臣营养品公司 用于预防和治疗过敏的益生菌衍生的无活力材料
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. FORSBERG等: "Pre- and post-natal Lactobacillus reuteri supplementation decreases allergen responsiveness in infancy", 《CLINICAL MECHANISMS IN ALLERGIC DISEASE》 *
PAOLA COCCORULLO等: "Lactobacillus reuteri (DSM 17938) in Infants with Functional Chronic Constipation: A Double-Blind, Randomized, Placebo-Controlled Study", 《THE JOURNAL OF PEDIATRICS》 *
SAMULI RAUTAVA等: "Probiotics Modulate Host-Microbe Interaction in the Placenta and Fetal Gut: A Randomized, Double-Blind, Placebo-Controlled Trial", 《NEONATOLOGY》 *
SAMULI RAUTAVA等: "Probiotics Modulate Host-Microbe Interactionin the Placenta and Fetal Gut: A Randomized,Double-Blind, Placebo-Controlled Trial", 《NEONATOLOGY》 *
陈萍英等: "临床干预对妊娠晚期细菌性阴道病不良妊娠结局的预防效果研究", 《中国妇幼保健》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739814A (zh) * 2018-07-24 2021-04-30 生命大地女神有限公司 使用能够增加腺苷水平的细菌菌株的治疗方法
CN112739814B (zh) * 2018-07-24 2023-12-08 生命大地女神有限公司 使用能够增加腺苷水平的细菌菌株的治疗方法

Also Published As

Publication number Publication date
WO2015177246A8 (en) 2016-01-14
US20170216375A1 (en) 2017-08-03
EP3145520A2 (en) 2017-03-29
WO2015177246A3 (en) 2016-03-03
KR20170005806A (ko) 2017-01-16
CL2016002732A1 (es) 2017-04-28
WO2015177246A2 (en) 2015-11-26
AU2015261869A1 (en) 2016-11-17
JP2017515881A (ja) 2017-06-15
MX2016015153A (es) 2017-03-07

Similar Documents

Publication Publication Date Title
CN106879253A (zh) 新生儿微生物组补充
US20250017988A1 (en) Probiotic Delivery Systems
Taylor et al. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial
Luoto et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial
ES2611277T3 (es) Péptidos contra una infección por rotavirus
TWI374745B (en) Use of a combination of bifidobacterium lactis bb-12 and lactobacillus rhamnosus gg for preventing or treating respiratory infections and acute otitis media in infants
Collado et al. Microbial ecology and host-microbiota interactions during early life stages
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
JP2019048857A (ja) 細菌株を含む組成物
EA031426B1 (ru) ПРИМЕНЕНИЕ Bifidobacterium lactis BL-04 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ
MX2012011270A (es) Pienso para acondicionar la flora intestinal de terneras.
WO2020063531A1 (zh) 副干酪乳杆菌et-22及其用途
JP6837442B2 (ja) 乳酸菌を活性化する方法
Juhl Necrotizing enterocolitis-classification and two initial steps towards prevention
CN115068591A (zh) 一种包含骨桥蛋白的益生菌组合物
Neu The developing intestinal microbiome: probiotics and prebiotics
JP2023550962A (ja) アトピー性疾患を予防、遅延、又は改善する方法
Herman et al. Prevention of IgE-mediated food allergy: emerging strategies through maternal and neonatal interventions
EP4210720B1 (en) Probiotic compositions for the treatment of acne
Ng et al. Primary Prevention of Allergy–Is It Feasible?
Lista et al. Functional nutrients in infants born by vaginal delivery or Cesarean section
Filipovic et al. Probiotics in allergic diseases
Whitney An Investigation into Differences in the Infant Intestinal Microbiome Based on Method of Delivery
Sadanov et al. First Phase of the Clinical trial of the AS-Probionorm Probiotic Medication for the treatment of Human Intestinal Infections
HK40081564A (zh) 一种包含骨桥蛋白的益生菌组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170620